Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2015

01-06-2015 | Endocrine Tumors

What Can We Learn from Intraoperative Parathyroid Hormone Levels that Do Not Drop Appropriately?

Authors: Heather Wachtel, MD, Isadora Cerullo, BA, Edmund K. Bartlett, MD, Rachel R. Kelz, MD, MSCE, Giorgos C. Karakousis, MD, Douglas L. Fraker, MD

Published in: Annals of Surgical Oncology | Issue 6/2015

Login to get access

Abstract

Background

Parathyroidectomy remains the only definitive treatment for primary hyperparathyroidism. We studied our large series of parathyroidectomies to identify factors predictive of failure to meet intraoperative parathyroid hormone (IOPTH) monitoring criteria.

Methods

We performed a retrospective cohort review of patients who underwent initial parathyroidectomy for primary hyperparathyroidism with IOPTH monitoring. Primary outcome was intraoperative failure, defined as failure to decrease IOPTH by ≥50 % and into normal range. Univariate and multivariate analyses were performed to determine factors associated with intraoperative failure. A subset analysis evaluated 6-month outcomes.

Results

Of 2,185 subjects, 5.0 % (n = 110) experienced intraoperative failure. The intraoperative failure group had more multigland disease (35.2 vs. 16.6 %, p < 0.001) and smaller glands (1.3 vs. 1.5 cm, p = 0.048) compared to patients who experienced intraoperative success. On multivariate analysis, PTH level was statistically, but not clinically, significantly associated with intraoperative failure (odds ratio 1.0, 95 % confidence interval 1.000–1.003). Persistent hyperparathyroidism was identified in 2.5 % (n = 15) of 592 patients with ≥6 month follow-up. Median IOPTH decrease was lower in patients with persistent hyperparathyroidism (67.1 vs. 85.8 %, p < 0.001). IOPTH criteria were 93.7 % sensitive and 40.0 % specific for eucalcemia 6 months postoperatively. Of 15 patients with persistent hyperparathyroidism, 7 underwent reoperation with a 100 % cure rate. Reoperative diagnoses included ectopic mediastinal glands (n = 3), hyperplasia (n = 3), and missed second adenoma (n = 1).

Conclusions

Intraoperative failure is associated with higher rates of multigland disease and smaller parathyroid glands. Patients with persistent disease had significantly lower decreases in IOPTH, but half of patients who experienced failure by IOPTH criteria were eucalcemic 6 months postoperatively. All patients undergoing reoperation experienced successful cure.
Literature
1.
Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol. 2009;71:485–93.CrossRef
2.
Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171–7.CrossRefPubMed
3.
Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122–9.CrossRefPubMedCentralPubMed
4.
Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am. 2009;89:1205–25.CrossRefPubMed
5.
Simental A, Ferris RL. Reoperative parathyroidectomy. Otolaryngol Clin North Am. 2008;41:1269–74, xii.
6.
7.
Hasse C, Sitter H, Brune M, Wollenteit I, Nies C, Rothmund M. Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results. World J Surg. 2002;26:1029–36. doi:10.​1007/​s00268-002-6664-2 CrossRefPubMed
8.
Karakas E, Muller HH, Schlosshauer T, Rothmund M, Bartsch DK. Reoperations for primary hyperparathyroidism—improvement of outcome over two decades. Langenbeck Arch Surg. 2013;398:99–106.CrossRef
9.
10.
11.
Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg. 1996;224:308–20.CrossRefPubMedCentralPubMed
12.
Cheung PS, Borgstrom A, Thompson NW. Strategy in reoperative surgery for hyperparathyroidism. Arch Surg. 1989;124:676–80.CrossRefPubMed
13.
Granberg PO, Johansson G, Lindvall N, et al. Reoperation for primary hyperparathyroidism. Am J Surg. 1982;143:296–300.CrossRefPubMed
14.
Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery. 1994;116:954–7.PubMed
15.
Caron NR, Sturgeon C, Clark OH. Persistent and recurrent hyperparathyroidism. Curr Treat Options Oncol. 2004;5:335–45.CrossRefPubMed
16.
Carsello CB, Yen TW, Wang TS. Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery. 2012;152:575–81.CrossRefPubMed
17.
Wang TS, Ostrower ST, Heller KS. Persistently elevated parathyroid hormone levels after parathyroid surgery. Surgery. 2005;138:1130–5.CrossRefPubMed
18.
Yen TW, Wilson SD, Krzywda EA, Sugg SL. The role of parathyroid hormone measurements after surgery for primary hyperparathyroidism. Surgery. 2006;140:665–72.CrossRefPubMed
19.
Karakousis GC, Han D, Kelz RR, et al. Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT). Surgery. 2007;142:845–50.CrossRefPubMed
20.
21.
Moretz WH 3rd, Watts TL, Virgin FW Jr, Chin E, Gourin CG, Terris DJ. Correlation of intraoperative parathyroid hormone levels with parathyroid gland size. Laryngoscope. 2007;117:1957–60.CrossRefPubMed
22.
Sebag F, Hubbard JG, Maweja S, Misso C, Tardivet L, Henry JF. Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism. Surgery. 2003;134:1038–41.CrossRefPubMed
23.
Civelek AC, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99 m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery. 2002;131:149–57.CrossRefPubMed
24.
Mihai R, Gleeson F, Buley ID, Roskell DE, Sadler GP. Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients. World J Surg. 2006;30:697–704. doi:10.​1007/​s00268-005-0338-9 CrossRefPubMed
25.
26.
Heller KS, Blumberg SN. Relation of final intraoperative parathyroid hormone level and outcome following parathyroidectomy. Arch Otolaryngol Head Neck Surg. 2009;135:1103–7.CrossRefPubMed
27.
28.
Chiu B, Sturgeon C, Angelos P. What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy. Surgery. 2006;140:418–22.CrossRefPubMed
29.
Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA. Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab. 1998;83:2658–65.CrossRefPubMed
30.
Rudberg C, Akerstrom G, Palmer M, et al. Late results of operation for primary hyperparathyroidism in 441 patients. Surgery. 1986;99:643–51.PubMed
31.
Doherty GM, Doppman JL, Miller DL, et al. Results of a multidisciplinary strategy for management of mediastinal parathyroid adenoma as a cause of persistent primary hyperparathyroidism. Ann Surg. 1992;215:101–6.CrossRefPubMedCentralPubMed
32.
Kraimps JL, Denizot A, Carnaille B, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d’Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg. 1996;20:808–12. doi:10.​4103/​2230-8210.​113774 CrossRefPubMed
33.
Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol. 2004;5:315–25.CrossRefPubMed
34.
Barry MK, van Heerden JA, Grant CS, Thompson GB, Khosla S. Is familial hyperparathyroidism a unique disease? Surgery. 1997;122:1028–33.CrossRefPubMed
Metadata
Title
What Can We Learn from Intraoperative Parathyroid Hormone Levels that Do Not Drop Appropriately?
Authors
Heather Wachtel, MD
Isadora Cerullo, BA
Edmund K. Bartlett, MD
Rachel R. Kelz, MD, MSCE
Giorgos C. Karakousis, MD
Douglas L. Fraker, MD
Publication date
01-06-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 6/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4201-9

Other articles of this Issue 6/2015

Annals of Surgical Oncology 6/2015 Go to the issue

Breast Oncology

Breast Cancer Screening at the Breast Examination Center of Harlem

Colorectal Cancer

Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results

Melanomas

Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

Endocrine Tumors

Assessing the Validity of Transcutaneous Laryngeal Ultrasonography (TLUSG) After Thyroidectomy: What Factors Matter?

Colorectal Cancer

Low Lymph Node Retrieval After Preoperative Chemoradiation for Rectal Cancer is Associated with Improved Prognosis in Patients with a Good Tumor Response

Hepatobiliary Tumors

Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases